Guggenheim Has Lowered Expectations for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its price objective decreased by research analysts at Guggenheim from $80.00 to $65.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim‘s price target would suggest a potential upside of 141.10% from the stock’s current price.

A number of other equities analysts have also weighed in on the company. Morgan Stanley lowered their price objective on Ionis Pharmaceuticals from $104.00 to $75.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 10th. Citigroup restated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 21st. TD Cowen cut their target price on Ionis Pharmaceuticals from $84.00 to $53.00 and set a “buy” rating for the company in a research note on Tuesday, November 10th. Wall Street Zen upgraded Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Raymond James Financial reissued an “outperform” rating and set a $54.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, November 9th. Nineteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Get Our Latest Analysis on Ionis Pharmaceuticals

Ionis Pharmaceuticals Trading Down 3.7%

IONS opened at $26.96 on Wednesday. The firm has a market capitalization of $4.49 billion, a price-to-earnings ratio of -8.12 and a beta of 0.43. The company’s 50 day simple moving average is $42.45 and its two-hundred day simple moving average is $64.02. Ionis Pharmaceuticals has a 1-year low of $26.55 and a 1-year high of $86.74. The company has a debt-to-equity ratio of 3.42, a current ratio of 5.43 and a quick ratio of 5.36.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The business had revenue of $242.72 million during the quarter, compared to analyst estimates of $178.17 million. During the same period in the prior year, the business earned ($0.80) earnings per share. The business’s revenue was up 54.8% compared to the same quarter last year. Analysts expect that Ionis Pharmaceuticals will post -3.57 EPS for the current fiscal year.

Insider Activity

In other Ionis Pharmaceuticals news, EVP Shannon Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the completion of the sale, the executive vice president directly owned 17,811 shares in the company, valued at $775,490.94. This trade represents a 7.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Hayden purchased 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 10th. The stock was bought at an average cost of $29.64 per share, for a total transaction of $148,200.00. Following the completion of the purchase, the director directly owned 27,000 shares in the company, valued at approximately $800,280. This trade represents a 22.73% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.81% of the company’s stock.

Institutional Trading of Ionis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in IONS. Handelsbanken Fonder AB raised its stake in Ionis Pharmaceuticals by 79.1% in the second quarter. Handelsbanken Fonder AB now owns 383,211 shares of the company’s stock valued at $30,385,000 after buying an additional 169,300 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Ionis Pharmaceuticals by 318.1% during the 1st quarter. Empowered Funds LLC now owns 103,141 shares of the company’s stock worth $7,745,000 after acquiring an additional 78,470 shares in the last quarter. TimesSquare Capital Management LLC acquired a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth about $48,690,000. Perceptive Advisors LLC purchased a new position in shares of Ionis Pharmaceuticals in the 1st quarter valued at about $37,845,000. Finally, Eagle Health Investments LP purchased a new position in shares of Ionis Pharmaceuticals in the 2nd quarter valued at about $15,428,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

See Also

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.